595 related articles for article (PubMed ID: 16412833)
1. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
2. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
Karabudak R; Kurne A; Guc D; Sengelen M; Canpinar H; Kansu E
J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
[TBL] [Abstract][Full Text] [Related]
3. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F
J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607
[TBL] [Abstract][Full Text] [Related]
4. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
Comabella M; Río J; Espejo C; Ruiz de Villa M; Al-Zayat H; Nos C; Deisenhammer F; Baranzini SE; Nonell L; López C; Julià E; Oksenberg JR; Montalban X
Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
6. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Bernal F; Elias B; Hartung HP; Kieseier BC
Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
8. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
Smeets TJ; Dayer JM; Kraan MC; Versendaal J; Chicheportiche R; Breedveld FC; Tak PP
Arthritis Rheum; 2000 Feb; 43(2):270-4. PubMed ID: 10693865
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[TBL] [Abstract][Full Text] [Related]
10. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
Dubois B; Leary SM; Nelissen I; Opdenakker G; Giovannoni G; Thompson AJ
J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
[TBL] [Abstract][Full Text] [Related]
11. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.
Sellner J; Greeve I; Leib SL; Mattle HP
Arch Neurol; 2008 May; 65(5):672-4. PubMed ID: 18474748
[No Abstract] [Full Text] [Related]
13. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S
J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
[TBL] [Abstract][Full Text] [Related]
16. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
17. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis.
Ichiyama T; Siba P; Suarkia D; Takasu T; Miki K; Kira R; Kusuhara K; Hara T; Toyama J; Furukawa S
J Neurol Sci; 2007 Jan; 252(1):45-8. PubMed ID: 17118404
[TBL] [Abstract][Full Text] [Related]
20. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]